Article Figures & Data
Figures
- Figure 1.
Primary Endpoint PFS (ITT Population).
- Figure 1.
Secondary Endpoint: OS (ITT).
Tools
Updated Efficacy Results from XELOX1/NO16966, a Randomized Phase 3 Trial in First-Line Metastatic Colorectal Cancer
Permalink:
Table of contents
- Article
- Summary
- Efficacy and Safety Findings from a Randomized Phase 3 Study of Capecitabine plus Oxaliplatin (XELOX) vs Infusional 5-FU/LV (FOLFOX-6) for Metastatic Colorectal Cancer
- Phase 3 Trial of Capecitabine plus Oxaliplatin (XELOX) vs 5-fluorouracil (5-FU), Leucovorin, and Oxaliplatin (FOLFOX4) as Second-Line Treatment for Patients with Metastatic Colorectal Cancer
- Updated Efficacy Results of the MOSAIC Trial, Including Survival, with a Median Follow-Up of Six Years
- The Impact of Dietary Patterns on Cancer Recurrence and Survival in Patients with Stage III Colon Cancer
- Figures & Data
- Info & Metrics
- eLetters
Cited By...
- No citing articles found.